#Israel #Caesarea #IceCure Medical #Cryoablation #SBRT

Advancements in Lung Cancer Treatment with IceCure's Cryoablation System

In a remarkable breakthrough for lung cancer treatment, IceCure Medical Ltd. has announced the successful results of its Cryoablation System when combined with Stereotactic Body Radiation Therapy (SBRT). The innovative approach showcases a 92% disease-specific survival rate over five years for patients with Non-Small Cell Lung Cancer (NSCLC). This development comes amidst the pressing need for improved treatment options, as lung cancer remains the leading cause of cancer-related deaths worldwide.

Understanding the Treatment and its Significance

Lung cancer holds the unfortunate title of being the most common form of cancer, with approximately 2.5 million new cases diagnosed globally each year. Traditionally, treatment options for patients classified as inoperable due to the stage of their disease have been limited, often leading to grim prognoses. However, IceCure's latest findings provide hope.

The study, titled “Long-term outcomes of combination therapy with stereotactic body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors ≥2 cm,” was authored by Dr. Hiroaki Nomori from the Kashiwa Kousei General Hospital in Japan, and included contributions from prestigious institutions such as Tokyo University. The results are published in the peer-reviewed journal PLOS One.

For this clinical study, 64 patients were treated with SBRT followed by cryoablation. The tumors involved had an average diameter of 2.7 cm, highlighting a focus on those considered larger or at a more advanced stage of the disease. Over a median follow-up period of 74 months, findings revealed a 5-year overall survival rate of 74%—a substantial increase compared to the 41% - 52% survival rates recorded with SBRT alone. Moreover, the 5-year disease-specific survival rate reached 92%, indicating robust treatment efficacy.

Key Outcomes and Future Implications

The clinical study yielded several noteworthy findings:

• - 5-Year Local Control Rate: 93%
• - 3-Year Disease-Specific Survival Rate: 96%
• - 5-Year Overall Survival Rate: 74%
• - Comparison with Surgery: Surgical interventions for NSCLC typically yield a 5-year overall survival rate of 67% - 82%, making this combination therapy a competitive alternative for inoperable patients.
• - Importantly, the study reported no treatment-related mortality, though the most common complication observed was pneumothorax, occurring in 40% of cases at a CTCAE grade 2 level.

Eyal Shamir, IceCure’s CEO, emphasized the significance of these findings, particularly in the context of expanding treatment options for inoperable patients. This potentially offers a minimally invasive alternative to surgical tumor removal, which has historically been the most common approach for cancer treatment.

The Promise of Innovation

IceCure's ProSense® system stands out as a minimally invasive cryosurgical tool harnessing the capabilities of liquid nitrogen to effectively target and destroy tumor tissues, presenting a more patient-friendly option compared to traditional methods. Prominently featured within this innovation is its capacity to facilitate accessible and efficient procedures in both office and hospital settings.

The implications of this breakthrough are especially relevant in key markets like the U.S. and Europe, where healthcare providers are continuously seeking effective, less invasive modalities to improve patient outcomes. The proven success of combining SBRT with cryoablation could fundamentally alter treatment paradigms and increase the survival rates of NSCLC patients.

In summary, IceCure Medical’s advancements in cryoablation therapy signal a pivotal shift in how we approach lung cancer treatment, underscoring the necessity for continuous innovation in oncology. As these results gain traction, they could potentially provide countless patients with a renewed sense of hope and an improved quality of life.

Conclusion

As studies like these emerge, it becomes increasingly clear that collaboration and innovation in medical technologies are crucial to combating formidable challenges like lung cancer. IceCure’s Cryoablation System exemplifies the potential to save lives and enhance treatment experiences for patients navigating the complexities of cancer care.